Use of FUBP1 inhibitors for treating hepatitis B virus infection
US11732262B2 · kind B2 · utility
0Cited by
3References
10Claims
0Family size
Inventors
Key dates
| Filing date | Oct 5, 2020 |
| Grant date | Aug 22, 2023 |
| Priority date | — |
| Expiry date | Oct 5, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.